Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) insider Mark S. Levine sold 4,361 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total transaction of $128,780.33. Following the sale, the insider now directly owns 322,878 shares in the company, valued at $9,534,587.34. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Immunovant Price Performance
Shares of Immunovant stock opened at $30.22 on Monday. The stock has a market capitalization of $4.42 billion, a P/E ratio of -15.66 and a beta of 0.66. The business has a 50 day simple moving average of $30.07 and a two-hundred day simple moving average of $28.92. Immunovant, Inc. has a 12 month low of $24.67 and a 12 month high of $45.58.
Immunovant (NASDAQ:IMVT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.07). During the same quarter in the previous year, the business earned ($0.57) earnings per share. As a group, research analysts anticipate that Immunovant, Inc. will post -2.41 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on IMVT
Hedge Funds Weigh In On Immunovant
Hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC grew its stake in Immunovant by 216.7% during the 2nd quarter. Quest Partners LLC now owns 2,610 shares of the company’s stock valued at $69,000 after acquiring an additional 1,786 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Immunovant during the 2nd quarter worth approximately $77,000. EntryPoint Capital LLC grew its position in shares of Immunovant by 288.8% in the first quarter. EntryPoint Capital LLC now owns 2,912 shares of the company’s stock valued at $94,000 after purchasing an additional 2,163 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Immunovant by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,294 shares of the company’s stock valued at $148,000 after purchasing an additional 934 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG purchased a new position in Immunovant during the third quarter worth approximately $261,000. 47.08% of the stock is owned by hedge funds and other institutional investors.
About Immunovant
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Further Reading
- Five stocks we like better than Immunovant
- Using the MarketBeat Dividend Tax Calculator
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Financial Services Stocks Investing
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Low PE Growth Stocks: Unlocking Investment Opportunities
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.